| 1. | Improved synthesis of adefovir dipivoxil
阿德福韦酯的合成工艺改进 |
| 2. | Determination of reference standard of adefovir dipivoxil by non - aqueous titration
非水滴定法测定阿德福韦酯对照品含量 |
| 3. | Examples of drugs in the class are lamivudine , entecavir and adefovir
这类药物的例子包括拉米夫定、恩替卡韦及阿德福韦。 |
| 4. | No amino acid substitutions known to confer adefovir resistance were detected in these patients
没有已知的，会造成阿德福韦抗药氨基酸替代物质在这些患者中发现。 |
| 5. | However , they cautioned , " careful monitoring of renal function is necessary , " since adefovir is known to cause kidney toxicity at high doses
但是，他们提醒， “细心观察肾脏功能是必需的， “因为阿德福韦已知会在高剂量情况下造成肾脏毒性。 |
| 6. | The rate of hepatitis b virus resistance to adefovir dipivoxil and the evolution of hepatitis b virus in lamivudine - resistant chronic hepatitis b patients with adv monotherapy
阿德福韦治疗拉米夫定耐药慢性乙型肝炎患者的耐药率及耐药株进化情况 |
| 7. | Prognosis of chronic hepatitis b has been improved significantly because of the clinical application of nucleoside / nucleotide analogues , such as lamivudine , adefovir dipivoxil , entecavir
拉米夫定、阿德福韦酯和恩替卡韦等核苷/核苷酸类似物的临床应用，大大改善了慢性乙型肝炎的预后。 |
| 8. | Background & aims : adefovir monotherapy is an established treatment modality for lamivudine - experienced patients with chronic hepatitis b , but it carries a significant risk of resistance in the long term
背景与目的：对于拉米夫定治疗过的慢性乙肝患者，用阿德福韦酯单药治疗是一种明确的治疗模式，但是从长远观点来看，这会带来严重的耐药风险。 |
| 9. | Some patients receiving adefovir dipivoxil ( hepsera ) at the approved dose of 10 mg daily for the treatment of chronic hepatitis b virus ( hbv ) infection have a suboptimal virological response characterized by a slow and moderate decrease in hbv replication
有些接受阿德福韦核准每天10毫克药量治疗慢性乙肝感染的患者常出现缓慢，中度减低病毒复制的不佳抗病毒效应。 |
